Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): CONSULTANT EXOCOBIO

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: EXOCOBIO

Objectives: 1. To understand that adipose stem cell exosome (ASCE) can be a paradigm shift in regenerative aesthetics & therapeutics
2. To find that ASCE can attenuate severe inflammation and promote skin barrier reconstruction in atopic dermatitis model
3. To know that ASCE can improve dupilumab facial redness (DFR) and acne scar
4. To know that ASCE can make scalp rejuvenation and hair loss prevention

Introduction: Exosomes, nano-sized extracellular vesicles, are the most important mediator for intercellular communication. For last years, the dual function of skin regeneration and anti-inflammation of ASCE has been well known from a number of research. These days, ASCEs are being developed as next generation regenerative therapeutics and aesthetics as well. From our various studies, it has been shown that ASCE can be an innovative biomaterial as regenerative therapeutics as well as regenerative aesthetics for treatment of atopic dermatitis, acne scar, facial redness, & scalp rejuvenation/hair loss.

Materials / method: Human adipose mesenchymal stem cell-derived exosomes (ASCE) and a specific formulation including ASCE were applied or treated for a variety of in vitro, in vivo, & clinical studies.

Results: 1. ASCE could reduce or modulate over-reactive inflammation in skin in atopic dermatitis model. The AD score was significantly improved and major proinflammatory cytokines including IL-4, IL-13, TLSP, & others were down-regulated.
2. ASCE could promote the de novo synthesis of ceramide and dihydroceramide, key lipid molecules in skin barrier formation, which led to the significant improvement of atopic dermatitis model.
3. When compared to PRP, ASCE and a specific formulation could successfully improve the results in terms of rejuvenating the scalp and reducing hair loss.

Conclusion: ASCE may serve as next generation technology with competitive advantages over conventional regenerative aesthetics or therapeutics, in terms of regeneration and anti-inflammation.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: Exosomes are nanoparticles that communicate with regional cells, and in many cases have replaced stem cells as a therapeutic modality. A new procedure for rejuvenation and skin resurfacing employs no energy based devices. Injection of microtoxin and dilute hyaluronic acid is followed by microneedling and application of topical exosomes. The immediate effect seen is due to sebum reduction, improvement in hydration and luminosity, and reduction of inflammation. Down time is under four hours. Treatment discomfort is minimal. Results are similar to fractional laser resurfacing.

Introduction: The current need for availability for Zoom calls has forced many formerly unselfconscious people to become acutely aware of their on camera appearance. A boom in aesthetic procedures has followed. Though laser resurfacing offers great value, the temporary deformity, resultant pattern marks, and prolonged erythema can limit acceptance by the work-at-home group. A new resurfacing option - more injectable than ablative-- can closely compete with results of laser without significant discomfort or down time.

Materials / method: In a 10 patient pilot cohort, 30 units of Bont-A were combined with 1 cc HA and diluted to a volume of 5 cc. Microinjections of 25 microliters were performed over the entire face. Dual wave RF microneedling with a setting of PW3, 2 passes, was performed. Topical exosome balm was then applied to the skin surface twice a day for 3 days. Patients were seen 3 days post-treatment, and again at 6 weeks and 3 months. Evaluation using Primos topographic mapping and waveform analysis was performed.

Results: Patients noted minimal down time with a maximum of 4 hours of transient erythema. No pattern marks were noted. Improvement in pore size, sebum production in the T zone, and improved luminosity were seen immediately. Pigment reduction and improvement of fine lines and skin surface irregularity was also noted. Patient previously treated with fractional laser noted instant improvement and no temporary deformity with the newer treatment method. Primos measurements showed a 14-22% improvement in skin roughness post-treatment.

Conclusion: Strong clinical improvement with little to no discomfort or temporary deformity was seen with the injectable/topical resurfacing method. Gentle microneedling was used to induce local inflammation which enhances the homing mechanism of topical exosomes. The procedure is cost effective and well tolerated. Longevity of results is currently noted at 6 months.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability